Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Betulinic Acid Derivatives as PET Tracers for Hypoxia-Induced Carbonic Anhydrase IX (CA IX) Expression.

Advances in experimental medicine and biology·2022
Same author

Improvement in thyroid ultrasound report quality with radiologists' adherence to 2015 ATA or 2017 TIRADS: a population study.

European thyroid journal·2022
Same author

Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity.

Case reports in endocrinology·2019
Same author

[Speech therapy after thyroid gland operations in Germany: analysis of routine data from 50,676 AOK patients].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2018
Same author

[Complications after thyroid gland operations in Germany : Further information and routine data analysis].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2017
Same author

[Complications after thyroid gland operations in Germany : A routine data analysis of 66,902 AOK patients].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2016

Related Experiment Video

Updated: May 29, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Anticancer metallotherapeutics in preclinical development.

G N Kaluderović1, R Paschke

  • 1Biozentrum, Martin-Luther-Universität Halle-Wittenberg, Weinbergweg 22, D-06120 Halle, Germany. goran.kaluderovic@chemie.uni-halle.de

Current Medicinal Chemistry
|September 17, 2011
PubMed
Summary

This review covers novel platinum and metal-based antitumor drugs in preclinical research, including advanced platinum complexes and alternative metal agents. It also explores strategies for water-insoluble drugs and nanodelivery systems for cancer treatment.

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Experiment Videos

Last Updated: May 29, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Drug Discovery

Background:

  • Cisplatin and its derivatives represent established platinum-based chemotherapy agents.
  • Ongoing research seeks novel anticancer drugs with improved efficacy and reduced toxicity.
  • Addressing challenges like drug solubility and delivery is crucial for effective cancer treatment.

Purpose of the Study:

  • To review recent advancements in platinum and non-platinum metal-containing antitumor drugs in preclinical development.
  • To outline innovative strategies in the design of novel anticancer agents.
  • To discuss solutions for water-insoluble drugs and the potential of nanodrug delivery systems.

Main Methods:

  • Review of recent preclinical studies on metal-based antitumor agents.
  • Analysis of strategies for developing unconventional platinum complexes (e.g., with biomolecules, organometallic, multinuclear).
  • Presentation of non-platinum metal drugs (Ru, Ga, Ti, Sn) and nanodelivery systems.

Main Results:

  • Several generations of cisplatin-based drugs have been developed.
  • Pioneering strategies include platinum complexes with biomolecules, organoplatinum, and multinuclear complexes.
  • Promising non-platinum metal drugs (Ru, Ga, Ti, Sn) and nanodelivery systems are emerging.

Conclusions:

  • The field of metal-based antitumor drugs is rapidly evolving with diverse strategies.
  • Novel platinum and non-platinum metal complexes show potential for cancer therapy.
  • Nanodrug delivery systems offer promising alternatives for challenging drug formulations and targeted delivery.